irinotecan has been researched along with apatinib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, M; Kim, R; Mahipal, A | 1 |
| Jiang, X; Li, C; Liang, L; Liu, L; Lu, P; Qiao, Y; Wang, L; Xia, Y; Yang, T | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J | 1 |
| Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M | 1 |
| Kan, ANC; Ku, DTL; Lam, YL; Liu, APY; To, KF; Yan, CLS; Yu, SH | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
2 review(s) available for irinotecan and apatinib
| Article | Year |
|---|---|
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asian People; Camptothecin; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Pyridines; Ramucirumab; Stomach Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Tegafur | 2020 |
3 trial(s) available for irinotecan and apatinib
| Article | Year |
|---|---|
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pilot Projects; Pyridines; Treatment Outcome | 2017 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids | 2019 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
2 other study(ies) available for irinotecan and apatinib
| Article | Year |
|---|---|
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide | 2023 |